Thelansis

Eye Pain Emerging Therapy and TPP Insights Thelansis’s “Eye Pain Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Eye Pain Overview Eye pain is a complex, non-specific clinical symptom rather than a distinct disease entity, arising from the noxious stimulation of ophthalmic trigeminal pathways due to corneal surface damage, intraocular inflammation, or elevated pressure. Key manifestations range from photophobia and epiphora to referred neuropathic dysesthesia. Diagnosis requires distinguishing distinct ocular pathologies via slit-lamp biomicroscopy, tonometry to measure intraocular pressure (IOP), and fluorescein staining to map epithelial defects. Rather than utilizing a generic triage approach, modern ophthalmic pharmacology targets t...

Locally Advanced or Metastatic HR+/HER2- Breast Cancer Market Outlook Thelansis’s “Locally Advanced or Metastatic HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook ...

HER2-Positive Metastatic Breast Cancer Emerging Therapy and TPP Insights Thelansis’s “HER2-Positive Metastatic Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs ...

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and levels Physician like...

Asthma Epidemiology Insights Thelansis’s “ ⁠ Asthma Epidemiology Insights and Forecast Report – 2020 To 2040 ″  provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Key business questions answered: 20-year historical and forecast data (2020–2040) Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes) Granular patient population coverage by year and geography Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc. Patient funnels ...

Alport Syndrome Market Access and Reimbursement Insights Thelansis’s “Alport Syndrome Market Access and Reimbursement Insights Report – 2026″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Alport Syndrome Overview Alport Syndrome is a hereditary nephropathy caused by COL4A3, COL4A4, or COL4A5 mutations disrupting type IV collagen, leading to glomerular basement membrane instability, progressive nephron loss, and sensorineural hearing impairment. It presents with microscopic hematuria, proteinuria, declining eGFR, and bilateral high-frequency hearing loss. Diagnosis combines electron microscopy showing GBM lamellation with genetic confirmation; proteinuria burden and eGFR...

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Asthma Overview Asthma is a chronic inflammatory airway disease characterised by variable, reversible airflow obstruction, bronchial hyperresponsiveness, and airway remodelling, driven predominantly by Th2-mediated eosinophilic inflammation — with type 2 cytokines IL-4, IL-5, and IL-13 central to its pathobiology — alongside non-eosinophilic neutrophilic and mixed phenotypes recognising asthma’s considerable biological heterogeneity. Genetic susceptibility, allergen sensitisation, respiratory viral infections, occupational exposures, and obesity interact as key disease determinants. Patients present with episodic wheeze, dyspnoea...

Global Chronic Obstructive Pulmonary Disease (COPD) Market Outlook Thelansis’s “Global Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Obstructive Pulmonary Disease (COPD) treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America). Global Chronic Obstructive Pulmonary Disease (COPD) Overview Chronic Obstructive Pulmonary Disease (COPD) is a significant global contributor to chronic illness and premature death. As the third leading cause of death worldwide, its prevalence and fatality rates are projected to rise in the coming d...

Global Multiple Sclerosis (MS) Market Outlook Thelansis’s “Global Multiple Sclerosis (MS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple Sclerosis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America). Global Multiple Sclerosis (MS) Overview Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating, and neurodegenerative disease of the central nervous system (CNS) fundamentally driven by autoreactive T-cell and B-cell infiltration across a compromised blood-brain barrier. This aberrant immune response orchestrates multifocal inflammatory cascades that p...

Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Market Outlook Thelansis’s “Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Overview Advanced or metastatic adenoid cystic carcinoma (ACC) is a rare, slow-growing but relentlessly progressive malignancy arising predominantly from salivary glands — major and minor — and occasionally from lacrimal glands, tracheobronchial tree, and breast, characterised by insidious...

Relapsed or Refractory Waldenstrom Macroglobulinemia (r/r WM) Market Outlook Thelansis’s “Relapsed or Refractory Waldenstrom Macroglobulinemia (r/r WM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Waldenstrom Macroglobulinemia (r/r WM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Waldenstrom Macroglobulinemia (r/r WM) Overview Relapsed or refractory Waldenström macroglobulinaemia (r/r WM) is a rare, indolent B-cell lymphoplasmacytic lymphoma characterised by clonal accumulation of IgM-secreting lymphoplasmacytic cells within the bone marrow, and defined by near-universal ...